Cargando…

Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection

The selective Bruton tyrosine kinase (BTK) inhibitor poseltinib has been shown to inhibit the BCR signal transduction pathway and cytokine production in B cells (Park et al. Arthritis Res. Ther. 18, 91, 10.1186/s13075-016-0988-z, 2016). This study describes the translation of nonclinical research st...

Descripción completa

Detalles Bibliográficos
Autores principales: Byun, Joo-Yun, Koh, Yi T., Jang, Sun Young, Witcher, Jennifer W., Chan, Jason R., Pustilnik, Anna, Daniels, Mark J., Kim, Young Hoon, Suh, Kwee Hyun, Linnik, Matthew D., Lee, Young-Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455565/
https://www.ncbi.nlm.nih.gov/pubmed/34548595
http://dx.doi.org/10.1038/s41598-021-98255-7